SIGLEC10 anticorps (AA 500-697)

N° du produit ABIN7875420

L’anticorps anti-SIGLEC10 Monoclonal Souris est utilisé pour la détection de SIGLEC10 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour SIGLEC10 anticorps (AA 500-697) (ABIN7875420)

Antigène: SIGLEC10 (Sialic Acid Binding Ig-Like Lectin 10 (SIGLEC10))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SIGLEC10 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: SIGLEC10-7582

Détail du produit anti-SIGLEC10 anticorps

Épitope: AA 500-697

Fonction: SIGLEC10 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant partial protein sequence (within amino acids 500-697) from the human protein was used as the immunogen for the SIGLEC10 antibody.

Isotype: IgG2, kappa

Information d'application

Indications d'application: Optimal dilution of the SIGLEC10 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the SIGLEC10 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur SIGLEC10

Antigène: SIGLEC10 (Sialic Acid Binding Ig-Like Lectin 10 (SIGLEC10))

Autre désignation: SIGLEC10

Sujet: Siglec-10 (sialic acid-binding Ig-like lectin 10) is a 697 amino acid protein belonging to the immunoglobulin superfamily. The N-terminal Ig-like domain of Siglec-10 contains a sialic acid-binding site and the C-terminal cytoplasmic region of Siglec-10 contains two immunoreceptor tyrosine-based inhibitor motifs (ITIMs), which are involved in the modulation of cellular responses through SH2 domains. With most expression in spleen, bone marrow and peripheral blood lymphocytes, such as monocytes, natural killer cells and eosinophils, it is likely that Siglec-10 functions as an inhibitory receptor in the immune response. Importantly, Siglec-10 mRNA is found to be highly upregulated in eosinophils at sites of inflammation in asthmatics, suggesting that Siglec-10 may be an appropriate target for new approaches of immunomodulatory therapy. There are six named isoforms of Siglec-10 that are a result of alternative splicing. All isoforms exists as single-pass transmembrane proteins, except for isoform 6, which is secreted.

UniProt: Q96LC7